Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enlivex Therapeutics Ltd (NQ: ENLV ) 1.380 -0.030 (-2.13%) Streaming Delayed Price Updated: 3:30 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Enlivex Therapeutics Ltd < Previous 1 2 Next > Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials April 14, 2023 Via ACCESSWIRE Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors April 12, 2023 Via ACCESSWIRE Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates April 04, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors April 03, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers March 20, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial February 23, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS February 15, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors January 25, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium January 04, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial December 07, 2022 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. Via TheNewswire.com What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers December 06, 2022 Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Via TheNewswire.com Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update December 05, 2022 From Enlivex Therapeutics Ltd Via GlobeNewswire First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM December 02, 2022 On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... Via TheNewswire.com Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors December 01, 2022 The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM. Via TheNewswire.com Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies November 28, 2022 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors November 15, 2022 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer November 10, 2022 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex to Present at the 4th Macrophage-Directed Therapies Summit October 03, 2022 From Enlivex Therapeutics Ltd Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.